Early decreases in blood eosinophil levels with reslizumab - 04/04/19
This study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc. |
|
Disclosure of potential conflict of interest: P. Chanez has provided consultancy services for Boehringer Ingelheim (BI), Centocor, GlaxoSmithKline (GSK), MSD, AstraZeneca (AZ), Novartis, Teva, Chiesi, SNCF, and ALK; has served on advisory boards for BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, Boston Scientific, ALK, and MSD; has received lecture fees from Boston Scientific, BI, Centocor, GSK, AZ, Novartis, Teva, and Chiesi; and has received industry-sponsored grants from ALK, BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, and Roche. M. McDonald was an employee of Teva Pharmaceuticals at the time the study was conducted. M. Garin is an employee of Teva Pharmaceuticals. K. Murphy has received consultancy and speaker fees and has participated in advisory boards for AZ, BI, Genentech, Greer, Meda, Merck, Mylan, Novartis, and Teva. |
Vol 143 - N° 4
P. 1653-1655 - avril 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?